{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:45:55Z","timestamp":1791618355951,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Pharmaceuticals Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ccell.2025.09.012","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:05:47Z","timestamp":1761235547000},"page":"2268-2281.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study"],"prefix":"10.1016","volume":"43","author":[{"given":"Jia","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengbo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianzeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiujie","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailun","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dihong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caigang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghua","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juxiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincai","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ce","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiushi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2025.09.012_bib1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1369\/0022155411410430","article-title":"Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target","volume":"59","author":"Stepan","year":"2011","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.ccell.2025.09.012_bib2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/genesandcancer.40","article-title":"Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications","volume":"6","author":"Shvartsur","year":"2015","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ccell.2025.09.012_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/dvdy.24242","article-title":"Trop2: from development to disease","volume":"244","author":"McDougall","year":"2015","journal-title":"Dev. Dyn."},{"key":"10.1016\/j.ccell.2025.09.012_bib4","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/14712598.2023.2198087","article-title":"Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer","volume":"23","author":"Belluomini","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ccell.2025.09.012_bib5","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2025.09.012_bib6","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab Govitecan in Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib7","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2025.09.012_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable\/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib9","article-title":"Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study","volume":"43","author":"Ahn","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ccell.2025.09.012_bib10","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/s41591-025-03630-w","article-title":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","volume":"31","author":"Yin","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ccell.2025.09.012_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085680","article-title":"Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial","volume":"389","author":"Fang","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.ccell.2025.09.012_bib12","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/s41591-025-03638-2","article-title":"Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1\/2 and phase 2 trials","volume":"31","author":"Zhao","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2025.09.012_bib13","doi-asserted-by":"crossref","first-page":"188902","DOI":"10.1016\/j.bbcan.2023.188902","article-title":"Targeting Trop-2 in cancer: Recent research progress and clinical application","volume":"1878","author":"Qiu","year":"2023","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"10.1016\/j.ccell.2025.09.012_bib14","doi-asserted-by":"crossref","first-page":"LB030","DOI":"10.1158\/1538-7445.AM2023-LB030","article-title":"Abstract LB030: SHR-A1921, a novel TROP-2 ADC with an optimized design and well-balanced profile between efficacy and safety","volume":"83","author":"He","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2025.09.012_bib15","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab Deruxtecan in Advanced or Metastatic HR+\/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib16","first-page":"9","volume":"200","author":"Rubinstein","year":"2025"},{"key":"10.1016\/j.ccell.2025.09.012_bib17","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group","volume":"18","author":"Fossella","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib18","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2025.09.012_bib20","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib21","doi-asserted-by":"crossref","first-page":"8623","DOI":"10.1200\/JCO.2024.42.16_suppl.8623","article-title":"Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd)","volume":"42","author":"Sands","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib22","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ccell.2025.09.012_bib23","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib24","doi-asserted-by":"crossref","first-page":"LBA5507","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5507","volume":"41","author":"Moore","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib25","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ygyno.2021.08.032","article-title":"Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)","volume":"163","author":"Gaillard","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib27","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.21.00334","article-title":"Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)","volume":"39","author":"Hamanishi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib28","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib29","doi-asserted-by":"crossref","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","article-title":"NCCN Guidelines\u00ae Insights: Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer, Version 3.2024","volume":"22","author":"Liu","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ccell.2025.09.012_bib30","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccell.2025.09.012_bib33","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib34","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib35","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2025.09.012_bib37","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","article-title":"Therapy of Advanced Non\u2013Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan","volume":"35","author":"Heist","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib38","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1200\/JCO.2024.42.16_suppl.8501","article-title":"ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome","volume":"42","author":"Planchard","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib39","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2025.09.012_bib40","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","article-title":"PL02.11 Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring is Predictive of Clinical Outcomes in TROPION-Lung 01","volume":"19","author":"Garassino","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2025.09.012_bib41","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1158\/1078-0432.CCR-24-0428","article-title":"Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1\/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin. Cancer Res."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610825004040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610825004040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:20:18Z","timestamp":1765210818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610825004040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1535610825004040"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2025.09.012","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2025.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}